The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice

Journal of Neuroimmunology

Volumn 229, Issue 1-2, 2010, Pages 192-203

  Aizman, Elizabeta ^a   Mor, Adi ^a   Chapman, Joab ^a   Assaf, Yaniv ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Experimental autoimmune encephalomyelitis; Farnesylthiosalycylic acid; FTS; Glatiramer acetate; Multiple sclerosis; Salirasib

Indexed keywords

FARNESYLTHIOSALICYLIC ACID; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; SALIRASIB; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS, CD3; CARRIER PROTEINS; CELL PROLIFERATION; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESOL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIC INFILTRATION; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; PEPTIDES; SALICYLIC ACIDS; SPINAL CORD; SPLEEN; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 78650205270     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.08.022     Document Type: Article

References (45)

1. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005, 25:8217-8228.
2. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Bruck W., Arnon R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 2008, 105:11358-11363.
3. Arnon R., Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J. Neural Transm. 2009, 116:1443-1449.
4. Aronovich R., Gurwitz D., Kloog Y., Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005, 210:781-788.
5. Auray, G., Facci, M.R., van Kessel, J., Buchanan, R., Babiuk, L.A., Gerdts, V., Differential activation and maturation of two porcine DC populations following TLR ligand stimulation. Molecular Immunology. 47, 2103-2111.
6. Begum-Haque S., Sharma A., Kasper I.R., Foureau D.M., Mielcarz D.W., Haque A., Kasper L.H. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2008, 204:58-65.
7. Belanis L., Plowman S.J., Rotblat B., Hancock J.F., Kloog Y. Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol. Biol. Cell 2008, 19:1404-1414.
8. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M., Kerlero de Rosbo N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 1996, 243:S14-S22.
9. Bertolotto A., Malucchi S., Capobianco M., Manzardo E., Guastamacchia G., Milano E., Audano L., Mutani R. Quantitative PCR reveals increased levels of tumor necrosis factor-alpha mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. J. Interferon Cytokine Res. 1999, 19:575-581.
10. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Pozo D., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl Acad. Sci. USA 2005, 102:13562-13567.
11. Gana-Weisz M., Halaschek-Wiener J., Jansen B., Elad G., Haklai R., Kloog Y. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin. Cancer Res. 2002, 8:555-565.
12. Giuliani F., Metz L.M., Wilson T., Fan Y., Bar-Or A., Yong V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 2005, 158:213-221.
13. Goldberg L., Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks PI3-kinase-dependent glioblastoma cell migration. Cancer Res. 2006, 66:11709-11717.
14. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
15. Haklai R., Gana-Weisz G., Elad G., Paz A., Marciano D., Egozi Y., Ben Baruch G., Kloog Y. Dislodgment and accelerated degradation of Ras. Biochemistry 1998, 37:1306-1314.
16. Hogh P., Oturai A., Schreiber K., Blinkenberg M., Jorgensen O.S., Ryder L., Paulson O.B., Sorensen P.S., Knudsen G.M. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult. Scler. 2000, 6:226-230.
17. Hong J., Li N., Zhang X., Zheng B., Zhang J.Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl Acad. Sci. USA 2005, 102:6449-6454.
18. Ilarregui J.M., Croci D.O., Bianco G.A., Toscano M.A., Salatino M., Vermeulen M.E., Geffner J.R., Rabinovich G.A. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009, 10:981-991.
19. Isaksson M., Ardesjo B., Ronnblom L., Kampe O., Lassmann H., Eloranta M.L., Lobell A. Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. Eur. J. Immunol. 2009, 39:2925-2935.
20. Kafri M., Kloog Y., Korczyn A.D., Ferdman-Aronovich R., Drory V., Katzav A., Wirguin I., Chapman J. Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J. Neuroimmunol. 2005, 168:46-55.
21. Kalinski P., Hilkens C.M., Wierenga E.A., Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 1999, 20:561-567.
22. Karussis D., Abramsky O., Grigoriadis N., Chapman J., Mizrachi-Koll R., Niv H., Kloog Y. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. 2001, 120:1-9.
23. Katzav A., Kloog Y., Korczyn A.D., Niv H., Karussis D.M., Wang N., Rabinowitz R., Blank M., Shoenfeld Y., Chapman J. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin. Exp. Immunol. 2001, 126:570-577.
24. Katzav A., Kloog Y., Korczyn A.D., Molina V., Blank M., Shoenfeld Y., Chapman J. Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. Immunobiology 2003, 207:47-50.
25. Killestein J., Kalkers N.F., Meilof J.F., Barkhof F., van Lier R.A., Polman C.H. TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS. Neurology 2001, 57:1129-1131.
26. La Mantia L., Munari L.M., Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 5, CD004678 2010.
27. Li L., Godfrey W.R., Porter S.B., Ge Y., June C.H., Blazar B.R., Boussiotis V.A. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 2005, 106:3068-3073.
28. Lisak R.P., Zweiman B., Blanchard N., Rorke L.B. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J. Neurol. Sci. 1983, 62:281-293.
29. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
30. Menge T., Weber M.S., Hemmer B., Kieseier B.C., von Budingen H.C., Warnke C., Zamvil S.S., Boster A., Khan O., Hartung H.P., Stuve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008, 68:2445-2468.
31. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., Wong W.M., Wang L., Su H., Chu T.H., Guo J., Zhang W., So K.F., Pepinsky B., Shao Z., Graff C., Garber E., Jung V., Wu E.X., Wu W. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
32. Mor A., Keren G., Kloog Y., George J. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur. J. Immunol. 2008, 38:1493-1502.
33. Mor A., Kloog Y., Keren G., George J. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. Eur. J. Pharmacol. 2009, 616:301-305.
34. Murphy A.C., Lalor S.J., Lynch M.A., Mills K.H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010, 24:641-651.
35. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J. Med. 2000, 343:938-952.
36. Reis e Sousa C. Dendritic cells in a mature age. Nat. Rev. Immunol. 2006, 6:476-483.
37. Rotblat B., Ehrlich M., Haklai R., Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008, 439:467-489.
38. Ruggieri M., Pica C., Lia A., Zimatore G.B., Modesto M., Di Liddo E., Specchio L.M., Livrea P., Trojano M., Avolio C. Combination treatment of glatiramer acetate and minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. J. Neuroimmunol. 2008, 197:140-146.
39. Schildknecht A., Brauer S., Brenner C., Lahl K., Schild H., Sparwasser T., Probst H.C., van den Broek M. FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:199-203.
40. Shalom-Feuerstein R., Plowman S.J., Rotblat B., Ariotti N., Tian T., Hancock J.F., Kloog Y. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res. 2008, 68:6608-6616.
41. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J. Med. 1998, 338:278-285.
42. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., Kapsenberg M.L. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 2003, 170:4483-4488.
43. Wakkach A., Fournier N., Brun V., Breittmayer J.P., Cottrez F., Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003, 18:605-617.
44. Weerth S.H., Rus H., Shin M.L., Raine C.S. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am. J. Pathol. 2003, 163:1069-1080.
45. Weisz B., Giehl K., Gana-Weisz M., Egozi Y., Ben-Baruch G., Marciano D., Gierschik P., Kloog Y. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999, 18:2579-2588.